Harnessing the immune system to treat cancer

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1130-1136

  Bhardwaj, Nina ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HEPATITIS B VACCINE; I KAPPA B; INTERLEUKIN 10; PEPTIDE; RITUXIMAB; TOLL LIKE RECEPTOR 9; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; GENE MUTATION; HEPATITIS B; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LIVER CANCER; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOTHERAPY; NEOPLASMS;

EID: 34248192226     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32136     Document Type: Review

References (124)

1. Ehrlich, P. 1909. Über den jetzigen Stand der Karzinomforschung [In German]. Ned. Tijdschr. Geneeskd. 5:273-290.
2. Burnet, M. 1964. Immunological factors in the process of carcinogenesis. Br. Med. Bull. 20:154-158.
3. Thomas, L. 1959. Reactions to homologous tissue antigens in relation to hypersensitivity [discussion]. In Cellular and humoral aspects of the hypersensitive states. H.S. Lawrence, editor. Hoeber-Harper. New York, New York, USA. 529-532.
4. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998.
5. Shankaran, V., et al. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111.
6. Street, S.E., et al. 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199:879-884.
7. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
8. Swann, J.B., and Smyth, M.J. 2007. Immune surveillance of tumors. J. Clin. Invest. 117:1137-1146. doi:10.1172/JCI31405.
9. Penn, I. 1988. Tumors of the immunocompromised patient. Annu. Rev. Med. 39:63-73.
10. Galon, J., et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960-1964.
11. Darnell, R.B., and Posner, J.B. 2006. Paraneoplastic syndromes affecting the nervous system. Semin. Oncol. 33:270-298.
12. Crowe, N.Y., Smyth, M.J., and Godfrey, D.I. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127.
13. Schreiber, R., Koebel, C., Vermi, W., Smyth, M., and Old, L.J. 2006. Cancer immunoediting: deciphering the complex interaction of the immune system with developing tumors. Presented at the Cancer Research Institute Annual Meeting on October 4-6, 2006, in New York, New York, USA. S-02.
14. Blank, C., et al. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64:1140-1145.
15. Brown, J.A., et al. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257-1266.
16. Dong, H., et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800.
17. Thompson, R.H., et al. 2004. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 101:17174-17179.
18. Munn, D.H., and Mellor, A.L. 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147-1154. doi:10.1172/JCI31178.
19. Munn, D., et al. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114:280-290. doi:10.1172/JCI200421583.
20. + dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167:708-714.
21. Orabona, C., et al. 2006. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood. 107:2846-2854.
22. Munn, D.H., Sharma, M.D., and Mellor, A.L. 2004. Ligation of B7-1/B7-2 by human CD4(+) T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172:4100-4110.
23. Fallarino, F., et al. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9:1069-1077.
24. Frumento, G., et al. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459-468.
25. Weber, W.P., et al. 2006. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J. Immunol. 36:296-304.
26. Terness, P., et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447-457.
27. Munn, D.H., et al. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 22:633-642.
28. Mellor, A.L., et al. 2005. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase- dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175:5601-5605.
29. Wingender, G., et al. 2006. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36:12-20.
30. Lee, J.H., et al. 2005. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11:107-112.
31. Gabrilovich, D.I., et al. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67:425; author reply 426.
32. Sica, A., and Bronte, V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155-1166. doi:10.1172/JCI31422.
33. Gallina, G., et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116:2777-2790. doi:10.1172/JCI28828.
34. Huang, B., et al. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-1131.
35. Serafini, P., Borrello, I., and Bronte, V. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16:53-65.
36. Colombo, M.P., and Mantovani, A. 2005. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 65:9113-9116.
37. De Palma, M., et al. 2005. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 8:211-226.
38. Muller, A.J., and Scherle, P.A. 2006. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer. 6:613-625.
39. Saccani, A., et al. 2006. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66:11432-11440.
40. O'Shea, J.J., Pesu, M., Borie, D.C., and Changelian, P.S. 2004. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3:555-564.
41. Kortylewski, M., et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11:1314-1321.
42. Luo, Y., et al. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116:2132-2141. doi:10.1172/JCI27648.
43. Mirza, N., et al. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66:9299-9307.
44. Curiel, T.J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117:1167-1174. doi:10.1172/JCI31202.
45. Liston, A., and Rudensky, A.Y. 2007. Thymic development and peripheral homeostasis of regulatory T cells. Curr. Opin. Immunol. 19:176-185.
46. Chen, W., et al. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:1875-1886.
47. Fu, S., et al. 2004. TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25- precursors. Am. J. Transplant. 4:1614-1627.
48. Fantini, M.C., et al. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149-5153.
49. Wang, H., et al. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 20:107-118.
50. Curiel, T., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
51. Carreras, J., et al. 2006. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 108:2957-2964.
52. Alvaro, T., et al. 2005. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11:1467-1473.
53. Yurchenko, E., et al. 2006. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203:2451-2460.
54. Dannull, J., et al. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-3633. doi:10.1172/JCI25947.
55. Steitz, J., Bruck, J., Lenz, J., Knop, J., and Tuting, T. 2001. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61:8643-8646.
56. Sutmuller, R.P., et al. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
57. Banerjee, D.K., Dhodapkar, M.V., Matayeva, E., Steinman, R.M., and Dhodapkar, K.M. 2006. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 108:2655-2661.
58. Hussain, S.P., Hofseth, L.J., and Harris, C.C. 2003. Radical causes of cancer. Nat. Rev. Cancer. 3:276-285.
59. Lin, W.-W., and Karin, M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117:1175- 1183. doi:10.1172/JCI31537.
60. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature. 441:431-436.
61. Luo, J.L., Kamata, H., and Karin, M. 2005. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115:2625-2632. doi:10.1172/JCI26322.
62. Hugot, J.P., et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:599-603.
63. Eckmann, L., and Karin, M. 2005. NOD2 and Crohn's disease: loss or gain of function? Immunity. 22:661-667.
64. Kurzawski, G., et al. 2004. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 64:1604-1606.
65. Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., and Karin, M. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297-305.
66. Bommert, K., Bargou, R.C., and Stuhmer, T. 2006. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer. 42:1574-1580.
67. Osborne, J., Moore, P.S., and Chang, Y. 1999. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum. Immunol. 60:921-927.
68. Cozen, W., et al. 2004. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 103:3216-3221.
69. Bongartz, T., et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 295:2275-2285.
70. Berg, D.J., et al. 1996. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 98:1010-1020.
71. Sellon, R.K., et al. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66:5224-5231.
72. Engle, S.J., et al. 2002. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res. 62:6362-6366.
73. Yu, H., Kortylewski, M., and Pardoll, D. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7:41-51.
74. + Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 115:313-325. doi:10.1172/JCI200522433.
75. Zorn, E., et al. 2006. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 108:1571-1579.
76. Hoentjen, F., Sartor, R.B., Ozaki, M., and Jobin, C. 2005. STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood. 105:689-696.
77. Schottelius, A.J., Mayo, M.W., Sartor, R.B., and Baldwin, A.S., Jr. 1999. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem. 274:31868-31874.
78. Nefedova, Y., et al. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:464-474.
79. Kao, J.H., and Chen, D.S. 2002. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2:395-403.
80. Mao, C., et al. 2006. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107:18-27.
81. Krieg, A.M. 2007. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117:1184-1194. doi:10.1172/JCI31414.
82. Krieg, A.M. 2006. Therapeutic potential of Tolllike receptor 9 activation. Nat. Rev. Drug Discov. 5:471-484.
83. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-746. doi:10.1172/JCI200523373.
84. Appay, V., et al. 2006. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 177:1670-1678.
85. Manegold, C. 2005. Addition of PF-3512676 (CpG 7909) to a taxane/platinum regimen for first-line treatment of unresectable non small cell lung cancer (NSCLC) improves objective response - phase II clinical trial. Eur. J. Cancer. 3(Suppl.):326.
86. Moseman, E.A., et al. 2004. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 173:4433-4442.
87. O'Neill, D., Adams, S., Bhardwaj, N. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 104:2235-2246.
88. Lu, W., Arraes, L., Ferreira, W., and Andrieu, J. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
89. Gilboa, E. 2007. DC-based cancer vaccines. J. Clin. Invest. 117:1195-1203. doi:10.1172/JCI31205.
90. Morelli, A.E., and Thomson, A.W. 2003. Dendritic cells under the spell of prostaglandins. Trends Immunol. 24:108-111.
91. Sporri, R., and Reis e Sousa, C. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6:163-170.
92. Gilboa, E., and Vieweg, J. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199:251-263.
93. Delamarre, L., Pack, M., Chang, H., Mellman, I., and Trombetta, E.S. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 307:1630-1634.
94. Delamarre, L., Couture, R., Mellman, I., and Trombetta, E.S. 2006. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203:2049-2055.
95. June, C.H. 2007. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117:1204-1212. doi:10.1172/JCI31446.
96. Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763.
97. Bollard, C.M., et al. 2006. In vivo expansion of LMP 1-and 2-specific T-cells in a patient who received donorderived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk. Lymphoma. 47:837-842.
98. Leen, A.M., et al. 2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12:1160-1166.
99. Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6:383-393.
100. Dudley, M.E., et al. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251.
101. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
102. Dudley, M.E., and Rosenberg, S.A. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer. 3:666-675.
103. Lou, Y., et al. 2004. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64:6783-6790.
104. Rapoport, A.P., et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11:1230-1237.
105. + T cells. J. Clin. Invest. 117:492-501. doi:10.1172/JCI30414.
106. Morgan, R.A., et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126-129.
107. Melero, I., et al. 1997. Monoclonal antibodies against the 4-1 BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682-685.
108. Korman, A.J., Peggs, K.S., and Allison, J.P. 2006. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90:297-339.
109. Quezada, S.A., Peggs, K.S., Curran, M.A., and Allison, J.P. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116:1935-1945. doi:10.1172/JCI27745.
110. Fallarino, F., et al. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4:1206-1212.
111. Hodi, F.S., et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100:4712-4717.
112. Phan, G.Q., et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100:8372-8377.
113. Freeman, G.J., et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-1034.
114. Iwai, Y., et al. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99:12293-12297.
115. Day, C.L., et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 443:350-354.
116. Petrovas, C., et al. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203:2281-2292.
117. Trautmann, L., et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202.
118. Vogt, L., et al. 2006. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J. Clin. Invest. 116:2817-2826. doi:10.1172/JCI25673.
119. Waldmann, T.A., and Morris, J.C. 2006. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv. Immunol. 90:83-131.
120. Reits, E.A., et al. 2006. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203:1259-1271.
121. Armeanu, S., et al. 2005. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65:6321-6329.
122. Borg, C., et al. 2004. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114:379-388. doi:10.1172/JCI200421102.
123. Zhang, B., et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204:49-55.
124. Obeid, M., et al. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54-61.